First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)

被引：0
|
作者：
Kok, M. [1 ]
Voorthuis, R. A. B. [2 ]
De Boo, L. [2 ]
van Rossum, A. G. J. [2 ]
Mandjes, I. [3 ]
Balduzzi, S. [4 ]
Chelushkin, M. [5 ]
Rosenberg, E. H. [6 ]
Horlings, H. M. [7 ]
Loo, C. E. [8 ]
Heijns, J. B. [9 ]
Agterhof, M. [10 ]
De Valk, B. [11 ]
Riel, A-M. V. [12 ]
Van der Velden, A. [13 ]
Dercksen, M. [14 ]
Imholz, A. [15 ]
van Leeuwen-Stok, A. E. [16 ]
Oosterkamp, H. M. [17 ]
Linn, S. [18 ]
机构：
[1] Netherlands Canc Inst, Med Oncol Dept, Amsterdam, Netherlands
[2] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Mol Pathol Dept, Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands
[4] NKI Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands
[5] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Tumor Biol & Immunol, Amsterdam, Netherlands
[6] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands
[7] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Pathol, Amsterdam, Netherlands
[8] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Radiol, Amsterdam, Netherlands
[9] Amphia Ziekenhuis Locat Molengracht, Oncol Dept, Breda, Netherlands
[10] St Antonius Hosp, Interne Geneeskunde, Nieuwegein, Netherlands
[11] Spaarne Hosp Hoofddorp, Med Oncol Dept, Hoofddorp, Netherlands
[12] ETZ Elisabeth Hosp, Med Oncol Dept, Tilburg, Netherlands
[13] Martini Hosp, Internal Med Dept, Groningen, Netherlands
[14] Maxima Med Ctr Veldhoven, Med Oncol, Veldhoven, Netherlands
[15] Deventer Ziekenhuis, Med Oncol, Deventer, Netherlands
[16] BOOG Study Ctr, Dutch Breast Canc Res Grp, Utrecht, Netherlands
[17] HMC Haaglanden Med Ctr Westeinde, Med Oncol, The Hague, Netherlands
[18] Antoni van Leeuwenhoek Hosp, NKI AVL Netherlands Canc Inst, Med Oncol Dept, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2258
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA20
引用
收藏
页码：1213 / 1213
页数：1
相关论文
共 50 条
  • [21] First-line chemo-immunotherapy with durvalumab, paclitaxel and carboplatin with or without anti-CD73 antibody oleclumab in advanced or metastatic triple-negative breast cancer: Preliminary results of the randomized phase II SYNERGY trial
    Debien, Veronique
    Maurer, Christian
    Aftimos, Philippe
    Clatot, Florian
    Loirat, Delphine
    Punie, Kevin
    Ghiringhelli, Francois
    Goncalves, Anhony
    Taylor, Donatienne
    Van den Mooter, Tom
    Ferrero, Jean-Marc
    Bonnefoi, Herve
    Canon, Jean-Luc
    Duhoux, Francois
    Poncin, Renaud
    Bazan, Fernando
    Isambert, Nicolas
    Barthelemy, Philippe
    Brandao, Mariana
    Kristanto, Paulus
    Ignatiadis, Michail
    Piccart, Martine
    Buisseret, Laurence
    CANCER RESEARCH, 2022, 82 (04)
  • [22] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
    Wang, Biyun
    Sun, Tao
    Zhao, Yannan
    Wang, Shusen
    Zhang, Jian
    Wang, Zhonghua
    Teng, Yue-E
    Cai, Li
    Yan, Min
    Wang, Xiaojia
    Jiang, Zefei
    Pan, Yueyin
    Luo, Jianfeng
    Shao, Zhimin
    Wu, Jiong
    Guo, Xiaomao
    Hu, Xichun
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [23] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
    Biyun Wang
    Tao Sun
    Yannan Zhao
    Shusen Wang
    Jian Zhang
    Zhonghua Wang
    Yue-E Teng
    Li Cai
    Min Yan
    Xiaojia Wang
    Zefei Jiang
    Yueyin Pan
    Jianfeng Luo
    Zhimin Shao
    Jiong Wu
    Xiaomao Guo
    Xichun Hu
    Nature Communications, 13
  • [24] Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).
    Yardley, Denise A.
    Cortes, Javier
    Coleman, Robert E.
    Conte, Pier Franco
    Brufsky, Adam
    O'Shaughnessy, Joyce
    Wright, Gail Lynn Shaw
    Eakle, Janice F.
    Wilks, Sharon
    Shtivelband, Mikhail
    Young, Robyn R.
    Bengala, Carmelo
    Li, Huiling
    Miller, Julie Ann
    Barton, Debora
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
    Brufsky, A.
    Kim, S. B.
    Zvirbule, Z.
    Eniu, A.
    Mebis, J.
    Sohn, J. H.
    Wongchenko, M.
    Chohan, S.
    Amin, R.
    Yan, Y.
    McNally, V
    Miles, D.
    Loi, S.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 652 - 660
  • [26] Primary Results From Impassion131, a Double-Blind Placebo-Controlled Randomized Phase 3 Trial of First-Line Paclitaxel +/- Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (11) : 11 - 12
  • [27] tnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer
    Yardley, D. A.
    Brufsky, A.
    Conte, P.
    Cortes, J.
    Glueck, S.
    Nabholtz, J-Ma
    O'Shaughnessy, J.
    Li, L.
    Barton, D.
    Fandi, A.
    Harbeck, N.
    CANCER RESEARCH, 2013, 73
  • [28] Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
    Miles, D.
    Gligorov, J.
    Andre, F.
    Cameron, D.
    Schneeweiss, A.
    Barrios, C.
    Xu, B.
    Wardley, A.
    Kaen, D.
    Andrade, L.
    Semiglazov, V
    Reinisch, M.
    Patel, S.
    Patre, M.
    Morales, L.
    Patel, S. L.
    Kaul, M.
    Barata, T.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 994 - 1004
  • [29] Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
    Brufsky, Adam
    Kim, Sung-Bae
    Zvirbule, Zanete
    Dirix, Luc Yves
    Eniu, Alexandru E.
    Carabantes, Francisco
    Izarzugaza, Yann
    Mebis, Jeroen
    Sohn, Joohyuk
    Wongchenko, Matthew
    Chohan, Saibah
    Amin, Reena
    McNally, V. A.
    Miles, David
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Final results of weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group
    Nikolaou, M.
    Saloustros, E.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Vamvakas, L.
    Kalbakis, K.
    Agelaki, S.
    Georgoulias, V.
    Mavroudis, D.
    ANNALS OF ONCOLOGY, 2016, 27
12345